Jeffrey Wasserstein Joins Nycomed US Inc.
MELVILLE, N.Y., Aug. 5 /PRNewswire/ — Nycomed US Inc. announced today the appointment of Jeff Wasserstein as its new Sr. Vice President, Business Development and Strategy. Jeff will be responsible for the evaluation and execution of Nycomed US growth strategies to meet US portfolio and financial needs through the execution of in-licensing, acquisitions and out-partnering opportunities. He will report to Steve Andrzejewski, CEO of Nycomed US.
Jeff has 20 years experience working in pharmaceutical companies, including Dr. Reddy’s and Schering Plough. Jeff founded, built and led Promius Pharma for Dr. Reddy’s as its President. Jeff holds a law degree from New York University School of Law and spent time working at Wachtell, Lipton, Rosen & Katz, specializing in mergers and acquisitions. Jeff also has a BA in Government from Franklin & Marshall College.
“We are delighted that Jeff will be joining us,” says Steve Andrzejewski, CEO of Nycomed US. “Jeff’s background in dermatology, commercial leadership and legal experience in M & A will provide us with the expertise to build a stronger pipeline and future for the Company.”
About Nycomed US
Nycomed US Inc. is a subsidiary of Nycomed and operates three divisions in the United States focused on specialty pharmaceuticals in dermatology. Founded in 1849, Fougera is a division of Nycomed US Inc. and is the leading manufacturer and distributor of a wide range of topical products. The PharmaDerm division is dedicated to developing and commercializing novel prescription products to treat diseases and conditions of the skin — the largest organ of the human body. Nycomed US also markets and sells Savage Laboratories products, which focus on emergency care. For more information on Fougera’s complete line of products, please call Fougera Customer Service at (800) 645-9833 or visit the company online at www.fougera.com. Information on PharmaDerm products can be found online at www.pharmaderm.com. More information is also available at www.nycomedus.com.
SOURCE Nycomed US Inc.